| Actively personalized vaccination trial for newly diagnosed glioblastoma N Hilf, S Kuttruff-Coqui, K Frenzel, V Bukur, S Stevanović, ... Nature 565 (7738), 240-245, 2019 | 850 | 2019 |
| Clinical relevance of tumour-associated macrophages MJ Pittet, O Michielin, D Migliorini Nature reviews Clinical oncology 19 (6), 402-421, 2022 | 482 | 2022 |
| Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies KR Parker, D Migliorini, E Perkey, KE Yost, A Bhaduri, P Bagga, M Haris, ... Cell 183 (1), 126-142. e17, 2020 | 399 | 2020 |
| Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas Y Yin, AC Boesteanu, ZA Binder, C Xu, RA Reid, JL Rodriguez, DR Cook, ... Molecular Therapy-Oncolytics 11, 20-38, 2018 | 177 | 2018 |
| CAR T-cell therapies in glioblastoma: a first look D Migliorini, PY Dietrich, R Stupp, GP Linette, AD Posey Jr, CH June Clinical Cancer Research 24 (3), 535-540, 2018 | 142 | 2018 |
| Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients D Migliorini, V Dutoit, M Allard, N Grandjean Hallez, E Marinari, V Widmer, ... Neuro-oncology 21 (7), 923-933, 2019 | 129 | 2019 |
| Allogeneic CAR T cells: an alternative to overcome challenges of CAR T cell therapy in glioblastoma D Martínez Bedoya, V Dutoit, D Migliorini Frontiers in immunology 12, 640082, 2021 | 124 | 2021 |
| The mitochondrial pyruvate carrier regulates memory T cell differentiation and antitumor function M Wenes, A Jaccard, T Wyss, N Maldonado-Pérez, ST Teoh, A Lepez, ... Cell Metabolism 34 (5), 731-746. e9, 2022 | 116 | 2022 |
| Glycan-directed CAR-T cells C Steentoft, D Migliorini, TR King, U Mandel, CH June, AD Posey Jr Glycobiology 28 (9), 656-669, 2018 | 105 | 2018 |
| Choosing the right tool for genetic engineering: clinical lessons from chimeric antigen receptor-T cells M Irving, E Lanitis, D Migliorini, Z Ivics, S Guedan Human Gene Therapy 32 (19-20), 1044-1058, 2021 | 83 | 2021 |
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies D Migliorini, N Mach, D Aguiar, R Vernet, BN Landis, M Becker, T McKee, ... Oncoimmunology 6 (8), e1338235, 2017 | 72 | 2017 |
| ChatGPT in glioma adjuvant therapy decision making: ready to assume the role of a doctor in the tumour board? J Haemmerli, L Sveikata, A Nouri, A May, K Egervari, C Freyschlag, ... BMJ Health & Care Informatics 30 (1), 2023 | 63 | 2023 |
| Repeated peripheral infusions of anti-EGFRvIII CAR T cells in combination with pembrolizumab show no efficacy in glioblastoma: a phase 1 trial SJ Bagley, ZA Binder, L Lamrani, E Marinari, AS Desai, MLP Nasrallah, ... Nature Cancer 5 (3), 517-531, 2024 | 56 | 2024 |
| Immunotherapy of malignant tumors in the brain: how different from other sites? V Dutoit, D Migliorini, PY Dietrich, PR Walker Frontiers in oncology 6, 256, 2016 | 53 | 2016 |
| Reductive carboxylation epigenetically instructs T cell differentiation A Jaccard, T Wyss, N Maldonado-Pérez, JA Rath, A Bevilacqua, JJ Peng, ... Nature 621 (7980), 849-856, 2023 | 50 | 2023 |
| BRAF/MEK double blockade in refractory anaplastic pleomorphic xanthoastrocytoma D Migliorini, D Aguiar, MI Vargas, A Lobrinus, PY Dietrich Neurology 88 (13), 1291-1293, 2017 | 45 | 2017 |
| Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma V Dutoit, D Migliorini, G Ranzanici, E Marinari, V Widmer, JA Lobrinus, ... Oncoimmunology 7 (2), e1391972, 2018 | 44 | 2018 |
| Recurrent multiple CNS hemangioblastomas with VHL disease treated with pazopanib: a case report and literature review D Migliorini, S Haller, D Merkler, A Pugliesi-Rinaldi, A Koka, K Schaller, ... CNS oncology 4 (6), 387-392, 2015 | 34 | 2015 |
| Cancer vaccines JT Schiller, DR Lowy, IH Frazer, OJ Finn, E Vilar, HK Lyerly, S Gnjatic, ... Cancer Cell 40 (6), 559-564, 2022 | 30 | 2022 |
| Exploratory study of the effect of IMA950/poly-ICLC vaccination on response to bevacizumab in relapsing high-grade glioma patients E Boydell, E Marinari, D Migliorini, PY Dietrich, A Patrikidou, V Dutoit Cancers 11 (4), 464, 2019 | 28 | 2019 |
Carl JuneUniversity of Pennsylvania確認したメール アドレス: upenn.edu
